I.L., Woods, S.C., et al. 1998. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 801:164-170.
I.L., Woods, S.C., et al. 1998.Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonistattenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 801:164-170.
I.L., Woods, S.C., et al. 1998. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 801:164-170.
GLP-1receptorantagonistexendin(9–39),thecyclicadenosinemo nophosphate(cAMP)inhibitorRp-cAMP,thePI3kinaseinhibitorLY 294002,andthep42/44mitogen-activatedproteinkinaseinhibitor UO126.Westernblotanalysisdemonstratedthephosphorylationof thepro-apoptoticpeptideBADintheGLP-1-treatedgroups.Wesh owforthefirsttimethatG...
Vamsi Kurra,Rohini Jeswani,Rajneet K. Oberoi,Jane R. Parnes,Narimon Honarpour,Joel Neutel&Jennifer L. Strande. (2024). A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.Nature Metabolism, volume 6, pages...
1 (GLP-1) receptor agonism to effectively reverse obesity, hyperglycaemia and dyslipidaemia in rodent models of metabolic disease. GLP-1-directed delivery of the NMDA receptor antagonist MK-801 affects neuroplasticity in the hypothalamus and brainstem. Importantly, targeting of MK-801 to GLP-1 ...
antagonistglp-1 peptideglucose levelpanningphage display libraryG protein-coupled receptors (GPCRs) are a group of seven-transmembrane receptor proteins that have proven to be successful drug targets. Antibodies are becoming an increasingly promising modality to target these receptors due to their unique...
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings Article Open access 05 February 2024 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Article Open access 18 September 2024 Molecular dyna...
The antagonist antibody data are by contrast to conclusions drawn from GIP transgenic mice that are resistant to DIO [54] and from the weight-reducing effects of newly developed GIPR agonists [64] (discussed earlier). To reconcile the agonist versus antagonist discrepancy, it has been proposed ...
(GLP-1R, Y1-R, and Y2-R, respectively) elicit Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets, thus revealing the counteracting effects of Y1-R and GLP-1R agonism. These agonists also promote insulin-independent Y1-R-...